FDA approves first drug for ultra-rare Alexander disease

The Food and Drug Administration on Sept. 3 approved the first medicine ever authorized to treat Alexander disease, an ultra-rare and often fatal genetic brain disorder for which doctors previously had nothing to offer beyond managing individual symptoms. The drug, Zanvastro (zilganersen), was developed by Ionis Pharmaceuticals of Carlsbad, California, and works by reducing the brain's production of a protein that builds up abnormally and damages the nervous system's structural support cells.

The clearance covers both children and adults and arrived 19 days ahead of the FDA's scheduled Sept. 22 decision deadline, according to the company. Alongside the approval, regulators awarded Ionis a Rare Pediatric Disease Priority Review Voucher, an incentive created to reward companies that develop treatments for severe childhood illnesses. Zanvastro is expected to reach U.S. pharmacies and infusion centers within weeks.

The trial numbers

The approval rests on a global, randomized, double-blind, controlled study that enrolled 54 participants ages 1.5 to 53 at 13 sites in eight countries, registered with the federal government as NCT04849741. Patients were assigned two-to-one to zilganersen or a control arm for a 60-week double-blind period, followed by extensions that will continue tracking participants into the next decade.

• Among patients age 5 and older, walking speed measured by a 10-meter walk test stabilized in treated patients versus continued decline in the control group, a 33.3 percent least-squares mean difference at week 61 that reached statistical significance (p=0.041).
• Among children ages 2 to 4, gross motor function scores improved by 22.9 points on a standard pediatric scale over the same period.
• Blood levels of GFAP, the protein the drug targets, fell 33.6 percent among treated patients by week 61, consistent with the drug's intended mechanism.
• Serious treatment-emergent adverse events occurred less often in treated patients (37.5 percent) than in the pooled control group (47.1 percent), though the drug carries a warning for aseptic meningitis, and the most common side effects — each affecting at least a quarter of patients — were vomiting, back pain, cough, headache and post-lumbar-puncture syndrome.

Zanvastro is given as a 50-milligram dose injected directly into spinal fluid once every three months, a delivery method common to antisense oligonucleotide drugs, which must bypass the blood-brain barrier to reach brain and spinal cord tissue. Ionis has built much of its business around that chemistry, previously co-developing the spinal muscular atrophy treatment nusinersen; Zanvastro marks the company's first product it will market on its own, rather than through a partner, according to its announcement of the approval.

A disease that had outrun medicine

Alexander disease is caused by mutations in the GFAP gene, which cause a structural protein to misfold and accumulate into clumps, called Rosenthal fibers, inside astrocytes — star-shaped cells that normally support and protect neurons. As those support cells fail, patients can lose motor control, speech, swallowing ability and bowel and bladder function, with symptoms ranging from seizures to spasticity depending on which of four recognized forms — neonatal, infantile, juvenile or adult-onset — a patient has. The infantile form, the most common and most severe, accounts for roughly 42 percent of documented cases and can be fatal within two years of onset, while adult-onset forms can progress over decades.

The disease's rarity has long made it difficult to study. A population-based estimate cited in the National Institutes of Health's clinical reference on the disorder puts prevalence at roughly one case per 2.7 million people, meaning the entire U.S. patient population likely numbers in the low hundreds. Ionis began enrolling patients in the pivotal trial in 2021; the study's primary follow-up period wrapped up in August 2025, and the FDA's priority review — reserved for therapies addressing unmet medical needs — compressed what is typically a longer review timeline.

Patients and researchers respond

Dr. Amy Waldman, a pediatric neurologist and medical director of the leukodystrophy program at Children's Hospital of Philadelphia who served as lead investigator on the trial, said the results give families a treatment option where none previously existed. "These results mark a meaningful step forward for families who have waited so long for innovation in Alexander disease," Waldman said, adding that the approval lets clinicians "move beyond managing individual manifestations of the disease to addressing its underlying biology."

Ionis Chief Executive Brett Monia called the clearance the company's first independent product launch from its neurology pipeline, and patient advocates described the moment as a turning point for a community accustomed to having no disease-modifying options at all.

"Today's approval represents a fundamental shift, changing the conversation from 'How do we manage this disease' to 'How can we treat it.'"

That assessment came from Emily Petty, president of End Alexander Disease, a patient advocacy organization that has funded research grants and supported families navigating the condition. Because so few people carry a diagnosis, the drug's real-world impact will play out largely within a small, tightly connected community of patients, caregivers and specialists at pediatric neurology centers such as CHOP's leukodystrophy program rather than in general practice.

What happens next

Ionis has not disclosed a list price for Zanvastro and has instead pointed to an "Every Step" support program intended to help patients navigate insurance coverage and access. The company holds worldwide rights to the drug but licensed development and commercialization outside the United States to the Italian pharmaceutical company Recordati in a deal reached in June, with regulatory filings in Europe and Japan expected in 2027. Industry coverage of the approval noted that early data suggested treating very young children might do more than stabilize their condition — it might improve motor function that had already begun to decline, a possibility researchers say warrants closer study as more patients start treatment.

The clinical trial's long-term extension is expected to continue collecting safety and efficacy data on participants for several more years, and Ionis and outside researchers will be watching whether the gains recorded in a 54-person study hold up as a broader population of patients, including those diagnosed as adults, begins using the drug outside a controlled trial setting.